Ankylosing Spondylitis News Archive

Greater Entheseal Damage, Inflammation Observed in Psoriatic Arthritis vs Ankylosing Spondylitis

Greater Entheseal Damage, Inflammation Observed in Psoriatic Arthritis vs Ankylosing Spondylitis

Patients with psoriatic arthritis had greater entheseal insertion damage scores compared with patients with ankylosing spondylitis.

Hospitalized Infection Risk Not Linked to DMARD, TNFi Use in Ankylosing Spondylitis

Hospitalized Infection Risk Not Linked to DMARD, TNFi Use in Ankylosing Spondylitis

No clear evidence links the risk for hospitalized infection and the use of DMARDs or anti-TNF agents in patients with ankylosing spondylitis.

Risk for Total Knee Arthroplasty Elevated in Ankylosing Spondylitis

Risk for Total Knee Arthroplasty Elevated in Ankylosing Spondylitis

The risk for primary total knee arthroplasty is elevated in young and middle-aged adults with ankylosing spondylitis.

Assessment of Simultaneous Occurrence of Ankylosing Spondylitis and Diffuse Idiopathic Skeletal Hyperostosis

Assessment of Simultaneous Occurrence of Ankylosing Spondylitis and Diffuse Idiopathic Skeletal Hyperostosis

Researchers explored the co-occurrence of ankylosing spondylitis and diffuse idiopathic skeletal hyperostosis.

TNFi Effectively Decreases Radiographic Progression in Early Ankylosing Spondylitis

TNFi Effectively Decreases Radiographic Progression in Early Ankylosing Spondylitis

Effective suppression of inflammation with tumor necrosis factor inhibitor therapy decreases radiographic progression in early ankylosing spondylitis.

Rates of Knee, Hip Arthroplasty Increasing Among Patients With Ankylosing Spondylitis

Rates of Knee, Hip Arthroplasty Increasing Among Patients With Ankylosing Spondylitis

Researchers observed increased rates of both knee and hip arthroplasties in older patients with ankylosing spondylitis.

Lower Cardiorespiratory Fitness Associated With Increased CVD Risk in Ankylosing Spondylitis

Lower Cardiorespiratory Fitness Associated With Increased CVD Risk in Ankylosing Spondylitis

Reduced cardiorespiratory fitness may be associated with increased risk for CVD in ankylosing spondylitis.

Risankizumab May Not Be Effective in Treatment of Ankylosing Spondylitis

Risankizumab May Not Be Effective in Treatment of Ankylosing Spondylitis

Treatment with risankizumab was not effective in reducing the signs and symptoms of ankylosing spondylitis at 12 weeks.

Positive Phase 3 Data Announced for Ixekizumab in Ankylosing Spondylitis

Positive Phase 3 Data Announced for Ixekizumab in Ankylosing Spondylitis

Results from a phase 3 study show positive results for ixekizumab in patients with ankylosing spondylitis.

Ankylosing Spondylitis Linked to Increased Prevalence of Left Ventricular Hypertrophy

Ankylosing Spondylitis Linked to Increased Prevalence of Left Ventricular Hypertrophy

Data strengthen the indication for performing a thorough CVD risk assessment in patients with inflammatory disorders.

Fatigue Affects Work Disability in Rheumatoid Arthritis, Ankylosing Spondylitis

Fatigue Affects Work Disability in Rheumatoid Arthritis, Ankylosing Spondylitis

Fatigue had a significant and independent effect on work disability measures in rheumatoid arthritis and ankylosing spondylitis.

Axial Psoriatic Arthritis and Ankylosing Spondylitis: Comparing Clinical, Radiologic Characteristics

Axial Psoriatic Arthritis and Ankylosing Spondylitis: Comparing Clinical, Radiologic Characteristics

It is unclear whether ankylosing spondylitis and axial psoriatic arthritis are part of a spectrum of the same disease, or whether they are separate diseases with overlapping features.

NSAID, TNFi Combination May Reduce Radiographic Progression in Ankylosing Spondylitis

NSAID, TNFi Combination May Reduce Radiographic Progression in Ankylosing Spondylitis

Dose-related use of NSAIDs together with TNFi in patients with ankylosing spondylitis has a synergistic effect in slowing radiographic progression.

Bimekizumab Linked to 12-Week Clinical Improvements in Ankylosing Spondylitis

Bimekizumab Linked to 12-Week Clinical Improvements in Ankylosing Spondylitis

Investigators assessed the 12-week efficacy and safety of bimekizumab in patients with active ankylosing spondylitis.

Biologic Therapy in Ankylosing Spondylitis: Insights From Social Media

Biologic Therapy in Ankylosing Spondylitis: Insights From Social Media

Researchers used data from social media to identify concerns and perceptions regarding biologic therapies.

Tofacitinib Reduces MRI Inflammation, May Improve Outcomes in Ankylosing Spondylitis

Tofacitinib Reduces MRI Inflammation, May Improve Outcomes in Ankylosing Spondylitis

Researchers assessed achievement of minimally important changes in SPARCC scores in biologic-naive patients with ankylosing spondylitis treated with tofacitinib or placebo.

Factors Associated With Neuropathic Pain in Ankylosing Spondylitis

Factors Associated With Neuropathic Pain in Ankylosing Spondylitis

A number of factors that include age, the presence of enthesitis, and depressive symptoms may be associated with neuropathic pain in ankylosing spondylitis.

Effects of Certolizumab Pegol Exposure on Pregnancy Outcomes in Women With Rheumatic Disease

Effects of Certolizumab Pegol Exposure on Pregnancy Outcomes in Women With Rheumatic Disease

Researchers sought to provide information on pregnancy outcomes, including major congenital malformations and other maternal and fetal adverse outcomes, in women treated with certolizumab pegol.

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

Nonmandatory transitioning from originator etanercept to biosimilar etanercept SB4 using a specifically designed communication strategy showed a slightly lower persistence rate and smaller decreases in disease activity.

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

TNFi therapy yielded favorable results in patients with AS or PsA, with progressively better responses between 4 months and 3 years.

FDA Label Update for Certolizumab Pegol Affects Women of Childbearing Age

FDA Label Update for Certolizumab Pegol Affects Women of Childbearing Age

The FDA has approved a label update to include pharmacokinetic data showing low transfer of certolizumab pegol through placenta and minimal transfer to breast milk from mother to infant.

TNF Inhibitor Response in Women vs Men With Ankylosing Spondylitis

TNF Inhibitor Response in Women vs Men With Ankylosing Spondylitis

Investigators evaluated sex differences in the effectiveness of tumor necrosis factor inhibitors in patients with ankylosing spondylitis.

Sustained Reduction in axSpA Joint Inflammation With Certolizumab Pegol

Sustained Reduction in axSpA Joint Inflammation With Certolizumab Pegol

Decreases in spinal and sacroiliac joint inflammation on MRI were maintained through 204 weeks with certolizumab pegol treatment.

Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

The risk for aortic regurgitation and cardiac rhythm abnormalities was evaluated in a nationwide cohort of patients with spondyloarthritis.

Biologic DMARDs Do Not Reduce Spinal Fracture Risk in Ankylosing Spondylitis

Biologic DMARDs Do Not Reduce Spinal Fracture Risk in Ankylosing Spondylitis

Spinal fracture-free survival among patients with AS was not significantly affected by the use of bDMARD therapy.

Use of Secukinumab in Ankylosing Spondylitis: Efficacy and Safety

Use of Secukinumab in Ankylosing Spondylitis: Efficacy and Safety

Investigators examined the long-term safety and efficacy of a subcutaneous maintenance dose of secukinumab 150 and 300 mg.

Do Biologic DMARDs Affect Spinal Fracture Risk in Ankylosing Spondylitis?

Do Biologic DMARDs Affect Spinal Fracture Risk in Ankylosing Spondylitis?

Male gender and the Charlson Comorbidity Index score contributed significantly to fracture risk in this population.

What Is the Best Site for Assessing Bone Loss in Ankylosing Spondylitis?

What Is the Best Site for Assessing Bone Loss in Ankylosing Spondylitis?

Research suggests that the best site to assess bone loss in patients with ankylosing spondylitis is the femoral neck.

Low-Dose CT Scans Detect Bone Proliferation in Ankylosing Spondylitis

Low-Dose CT Scans Detect Bone Proliferation in Ankylosing Spondylitis

Low-dose computed tomography detects more bone proliferation in patients with ankylosing spondylitis compared with conventional radiography.

Discontinuation of Biosimilar Infliximab Associated With Subjective Complaints

Discontinuation of Biosimilar Infliximab Associated With Subjective Complaints

Transitioning from an originator agent to its biosimilar has the potential to reduce healthcare costs without compromising outcomes.

Etanercept for Spondyloarthritis: Impact on Disease Progression

Etanercept for Spondyloarthritis: Impact on Disease Progression

The use of tumor necrosis factor inhibitors to modify structural changes in axial spondyloarthritis may prevent progression to spinal disease.

Endothelial Function Improves With Methotrexate, Anti-TNF Therapy in Inflammatory Arthritis

Endothelial Function Improves With Methotrexate, Anti-TNF Therapy in Inflammatory Arthritis

Although the effect of antirheumatic drugs on inflammatory arthritic conditions has not been fully elucidated, treatment with methotrexate and tumor necrosis factor inhibitors has been found to improve endothelial dysfunction in this population.

Secukinumab Long-Term Reduction of Radiographic Progression in Ankylosing Spondylitis

Secukinumab Long-Term Reduction of Radiographic Progression in Ankylosing Spondylitis

For patients with ankylosing spondylitis, secukinumab may reduce radiographic progression and remain effective in the long-term.

Ankylosing Spondylitis Associated With Higher Risk for Cardiovascular Events

Ankylosing Spondylitis Associated With Higher Risk for Cardiovascular Events

The risk for cerebrovascular accidents and myocardial infarctions was assessed in patients with ankylosing spondylitis.

Online Consultation System Benefits Rheumatic Disease Management

Online Consultation System Benefits Rheumatic Disease Management

The SSDM series of applications is cost-effective for patients of rheumatologists.

Long-Term Safety of Adalimumab in Immune-Related Diseases Analyzed

Long-Term Safety of Adalimumab in Immune-Related Diseases Analyzed

Investigators sought to determine the long-term safety of adalimumab use in patients with arthritis and other immune-related diseases.

FDA Approves Simponi Aria For Active Ankylosing Spondylitis, Psoriatic Arthritis

FDA Approves Simponi Aria For Active Ankylosing Spondylitis, Psoriatic Arthritis

Simponi Aria has been approved by the FDA for treating PsA or ankylosing spondylitis.

Predictors of Accelerated Atherosclerosis in Spondyloarthritis Without Overt CVD

Predictors of Accelerated Atherosclerosis in Spondyloarthritis Without Overt CVD

Predictors of subclinical accelerated atherosclerosis were examined in a recent study of patients with spondyloarthritis without overt cardiovascular disease.

Minimal Transfer of Certolizumab Pegol to Mature Breast Milk

Minimal Transfer of Certolizumab Pegol to Mature Breast Milk

The first lactation study of its kind evaluated whether a biologic drug is transferred into mature breast milk

FDA Approval of Biosimilar Cyltezo for Multiple Indications

FDA Approval of Biosimilar Cyltezo for Multiple Indications

Cyltezo subcutaneous injection has been approved by the FDA.

BMI and Treatment Response to TNF Inhibitors in Ankylosing Spondylitis

BMI and Treatment Response to TNF Inhibitors in Ankylosing Spondylitis

In patients with AS, those with a BMI in the overweight or obese range had a lower likelihood of clinical improvement with tumor necrosis factor inhibitor therapy.

Nonradiographic Axial Spondyloarthritis May Be Revealed by MRI

Nonradiographic Axial Spondyloarthritis May Be Revealed by MRI

A study analyzes whether underlying sacroiliac erosions may be present in patients with nonradiographic axial spondylarthritis who have normal radiographs.

Syndesmophytes A Superior Imaging Marker of Spinal Fusion than ZJ Fusion

Syndesmophytes A Superior Imaging Marker of Spinal Fusion than ZJ Fusion

In ankylosing spondylitis, syndesmophytes are a more useful imaging marker of spinal fusion.

Markers of Radiographic Spinal Progression in Ankylosing Spondylitis

Markers of Radiographic Spinal Progression in Ankylosing Spondylitis

Serum leptin and high molecular weight adiponectin have an inverse relationship with radiographic spinal progression in patients with ankylosing spondylitis.

Early Predictors of Poor Long-Term Treatment Response in Spondyloarthritis

Early Predictors of Poor Long-Term Treatment Response in Spondyloarthritis

Determining which patients are unlikely to respond to therapy early on may help reduce unnecessary treatment and contain costs.

Anti-TNF- Rx Improves Sleep in Ankylosing Spondylitis

Anti-TNF-α Rx Improves Sleep in Ankylosing Spondylitis

Patients saw a reduction in PSQI scores, but no change in polysomnography parameters.

Abnormal Chest Radiograph in Uveitis Often Sarcoidosis

Abnormal Chest Radiograph in Uveitis Often Sarcoidosis

Patients with panuveitis more often had biopsy-confirmed sarcoidosis than those with other anatomical locations of uveitis (20% vs 4%).

Systemic Therapy Associated With Improved Visual Acuity in Uveitis

Systemic Therapy Associated With Improved Visual Acuity in Uveitis

At seven-year follow-up, visual acuity was better with systemic therapy than with intravitreous fluocinolone acetonide implants.

MTX  Adalimumab Effective in JIA-Associated Uveitis

MTX + Adalimumab Effective in JIA-Associated Uveitis

In children with active juvenile idiopathic arthritis, the treatment combination controls eye inflammation.

Biosimilar Confidence: Physician-Patient Communication Sets the Tone

Biosimilar Confidence: Physician-Patient Communication Sets the Tone

Jonathan Krant, MD, FACP, confronts the issues surrounding biosimilar substitution for biologic treatments.

Etanercept May Increase Risk of Anterior Uveitis in Ankylosing Spondylitis

Etanercept May Increase Risk of Anterior Uveitis in Ankylosing Spondylitis

Researchers examined whether different TNF inhibitors were associated with different rates of anterior uveitis in patients with ankylosing spondylitis undergoing treatment with adalimumab, etanercept, or infliximab.

High-dose Steroids Increase Serious Infection Risk in Pregnant Women With Inflammatory Conditions

High-dose Steroids Increase Serious Infection Risk in Pregnant Women With Inflammatory Conditions

An observational cohort study of 4961 women with completed pregnancies and a recorded diagnosis of systemic inflammatory conditions.

Minimal Amount of TNF Inhibitor Transfers to Breast Milk, Study Finds

Minimal Amount of TNF Inhibitor Transfers to Breast Milk, Study Finds

Study evaluated breast milk samples from 17 lactating mothers diagnosed with rheumatoid arthritis, Crohn's disease, psoriatic arthritis, and axial spondyloarthritis/ankylosing spondylitis.

The Handoff: Your Week in Rheumatology News - 3/3/17

The Handoff: Your Week in Rheumatology News - 3/3/17

Connecticut considers rheumatoid arthritis and fibromyalgia for medical marijuana treatment, while Lyme disease-carrying deer ticks continue to invade Michigan. All this and more in this week's edition.

Arthritis and Incident Myocardial Infarction Risk

Arthritis and Incident Myocardial Infarction Risk

Research comes from meta-analysis of 25 population-based studies on 5 major forms of arthritis.

NSAIDs Limited For Providing Back Pain Relief

NSAIDs Limited For Providing Back Pain Relief

Only 1 in 6 patients who take NSAIDs for back pain achieved benefits from the therapy.

ASAS/EULAR Revise Axial Spondyloarthritis Management Recommendations

ASAS/EULAR Revise Axial Spondyloarthritis Management Recommendations

Collaborative document provides guidance on non-pharmacological and pharmacological management in patients with axial spondyloarthritis.

Risk Factors For NSAID Hypersensitivity Reaction Identified

Risk Factors For NSAID Hypersensitivity Reaction Identified

A retrospective cohort study found 1 in 5 non-steroidal anti-inflammatory drug (NSAID) adverse drug reactions is a hypersensitivity reaction.

Treatment Efficacy and Clinical Burden in Nonradiographic Axial Spondyloarthritis vs Ankylosing Spondylitis

Treatment Efficacy and Clinical Burden in Nonradiographic Axial Spondyloarthritis vs Ankylosing Spondylitis

New research compared treatment efficacy by drug class and clinical and humanistic burdens of nr-axSpA with those of AS.

Janssen Seeks FDA Approval for Golimumab in PsA and AS

Janssen Seeks FDA Approval for Golimumab in PsA and AS

The sBLAs included data from two Phase 3 studies that assessed the safety and efficacy of Simponi Aria 2mg/kg infusion every 8 weeks after two starter doses at Weeks 0 and 4 in adults with active psoriatic arthritis.

Greater AS Partial Remission With IFX + NSAID vs NSAID Monotherapy

Greater AS Partial Remission With IFX + NSAID vs NSAID Monotherapy

Data from a recent trail show patients with early axial spondyloarthritis (axSpA) had better outcomes when treated with IFX + NPX than with NPX monotherapy.

Cervical BME Correlates With Neck Pain in RA and AS

Cervical BME Correlates With Neck Pain in RA and AS

Study examines the relationship between bone marrow edema and neck pain in patients with rheumatoid arthritis and ankylosing spondylitis.

Reproducibility of SIJ Classification in Axial SpA

Reproducibility of SIJ Classification in Axial SpA

The reproducibility of radiographic SIJ classification and potential drivers of disagreement were examined in a SpA inception cohort.

Matching-Adjusted Indirect Comparison of Secukinumab, Adalimumab in AS

Matching-Adjusted Indirect Comparison of Secukinumab, Adalimumab in AS

Secukinumab treatment was associated with higher ASAS 20 response rates at weeks 16, 24, and 52 and ASAS 40 at weeks 24 and 52 compared with treatment with adalimumab.

Comparative Efficacy of TNF-α Inhibitors Evaluated in AS

Comparative Efficacy of TNF-α Inhibitors Evaluated in AS

In this meta-analysis, the researchers found that all TNF-α inhibitors were more effective at treating AS than placebo in direct comparisons, but no differences in efficacy or safety were found between individual TNF-α inhibitors in indirect comparisons.

Updated EULAR Guidelines for RA CVD Risk Management

Updated EULAR Guidelines for RA CVD Risk Management

The European League Against Rheumatism has released updated management guidelines to address cardiovascular disease risk assessment in patients with rheumatoid arthritis and other inflammatory arthritides.

Adalimumab Biosimilar Amjevita Approved by FDA

Adalimumab Biosimilar Amjevita Approved by FDA

A biosimilar to adalimumab (adalimumab-atto (Amjevita®, Amgen) has been approved by the US Food and Drug Administration (FDA) to treat moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis.

Comparative Malignancy Risks in AS vs General Population

Comparative Malignancy Risks in AS vs General Population

Various studies have examined the link between ankylosing spondylitis (AS) and multiple malignances and autoimmune diseases.

Delayed Recognition of Spondyloarthritis: Diagnostic Challenges & Opportunities

Delayed Recognition of Spondyloarthritis: Diagnostic Challenges & Opportunities

Delayed diagnosis is associated with worse outcomes and poor treatment responses in patients with spondyloarthritis. Andrew Vreede, MD, University of Wisconsin School of Medicine and Public Health, presents a talk about how delays in diagnosing spondyloarthritis can affect access to therapy and long-term outcomes.

Effects of Colchicine Use on CVD, Mortality in Gout

Effects of Colchicine Use on CVD, Mortality in Gout

While colchicine may reduce risk of a second CV event in the general population, there is limited research on how colchicine may be used for control, treatment, or prevention.

Risk Factors Associated With Increased Uveitis Incidence in AS

Risk Factors Associated With Increased Uveitis Incidence in AS

Hip-joint lesions, number of affected peripheral arthritis joints, ASO, and CIC were found to be associated with higher rates of uveitis in AS.

Clinical Implications of the Recommended Approval of 2 Biosimilars: Interview With Allan Gibofsky MD

Clinical Implications of the Recommended Approval of 2 Biosimilars: Interview With Allan Gibofsky MD

Rheumatology Advisor speaks with Allan Gibofsky, MD, a professor of medicine and public health at Weill Cornell Medical College and an attending rheumatologist at Hospital for Special Surgery in New York, about the recent panel recommendation for FDA approval of biosimilar versions of adalimumab and etanercept.

Clinical Risk Factors Associated With Vertebral Fractures in AS

Clinical Risk Factors Associated With Vertebral Fractures in AS

Patients with AS frequently present with radiographic vertebral fractures, a risk that is more pronounced with older patients, baseline low bone mineral density and those with advanced disease.

AS Disease Activity Associated With Decreased Total Lean Mass

AS Disease Activity Associated With Decreased Total Lean Mass

Male patients with ankylosing spondylitis had significant decreases in both total and appendicular lean mass, which were both related to higher disease activity and bone loss.

FDA Briefing Report on ADA Biosimilar: Will More Options Soon Be Available?

FDA Briefing Report on ADA Biosimilar: Will More Options Soon Be Available?

The manufacturer of an adlimumab biosimilar has filed a biologics license application (BLA) with the FDA

Only One-Third of AS Cases Managed by Specialists

Only One-Third of AS Cases Managed by Specialists

In the first study comparing simultaneous estimates of ankylosing spondylitis (AS) management by PCPs and rheumatologists, researchers found that only approximately one-third of patients with clinically diagnosed AS were being managed by specialists

Adalimumab Gains FDA Approval for Noninfectious Uveitis

Adalimumab Gains FDA Approval for Noninfectious Uveitis

The U.S. Food and Drug Administration has approved adalimumab (Humira®, Abbvie), a potent blocker of tumor necrosis factor alpha, for the treatment of non-infectious intermediate, posterior, and panuveitis

Can Markers of Cartilage Collagen Metabolism Aid in PsA and AxSpA Dx?

Can Markers of Cartilage Collagen Metabolism Aid in PsA and AxSpA Dx?

A biomarker of collagen turnover in spondyloarthropathies may aid in early diagnosis and treatment

Comparing Relative Risks of CV Events in AS and RA

Comparing Relative Risks of CV Events in AS and RA

Researchers assessed incidence rates of age and sex-adjusted cardiovascular disease in patients with ankylosing spondylitis and rheumatoid arthritis, comparing these rates to those of the general population.

Paradoxical Activation of TNF-Regulatory Functions by Adalimumab

Paradoxical Activation of TNF-Regulatory Functions by Adalimumab

Therapeutic anti-TNF antibodies, long thought to act primarily via blockade of proinflammatory soluble TNF, appear to also bind membrane-bound TNF supporting regulatory T-cell expansion suppressing further inflammation.

Increased CVD Risk in Middle Aged Men With Newly Diagnosed AS

Increased CVD Risk in Middle Aged Men With Newly Diagnosed AS

In a large cohort study, men 60 to 69 years of age with newly diagnosed AS were at a higher risk for CVD at 5 years follow-up compared to the general population.

Multidisciplinary Partnerships in the Management of Uveitis in Patients With Rheumatic Disease

Multidisciplinary Partnerships in the Management of Uveitis in Patients With Rheumatic Disease

Uveitis may occur in patients with ankylosing spondylitis, juvenile rheumatoid arthritis, Behcet's disease, and HLA B27-associated seronegative spondyloarthropathies. Prompt initiation of treatment may improve clinical outcomes, emphasizing the importance of collaboration between rheumatologists and ophthalmologists.

Calprotectin as a Reliable Surrogate Marker for Bowel Inflammation in SpA?

Calprotectin as a Reliable Surrogate Marker for Bowel Inflammation in SpA?

Fecal levels of calprotectin have been used as biomarkers of inflammatory bowel disease activity, and researchers speculated that its levels may be viable markers for bowel involvement in spondyloarthritis as well.

Diagnoses Associated With Inpatient Mortality in AS

Diagnoses Associated With Inpatient Mortality in AS

Cervical spine fracture was identified as the leading cause of in-hospital mortality in patients with ankylosing spondylitis.

Factors Influencing Rates of Adherence to Medications for Arthritis

Factors Influencing Rates of Adherence to Medications for Arthritis

The current research on adherence to interventions for arthritis has shown inconsistent impacts on disease outcomes.

Effects of Switching Patients With AS to the Infliximab Biosimilar CT-P13

Effects of Switching Patients With AS to the Infliximab Biosimilar CT-P13

Results were reported from an open-label, single-arm, multicenter extension study assessing the long-term efficacy and safety of multiple doses of the infliximab biosimilar CT-P13 in patients with ankylosing spondylitis.

Predictors of Adverse Work Outcomes in Ankylosing Spondylitis

Predictors of Adverse Work Outcomes in Ankylosing Spondylitis

Work disability can have economic consequences for patients with chronic diseases, but it can also impact self-esteem, emotional life, and autonomy of the persons experiencing the disease.

Role of Non-Conventional HLA-B27 in the Pathogenesis of Spondyloarthritis

Role of Non-Conventional HLA-B27 in the Pathogenesis of Spondyloarthritis

Researchers evaluated the possible role that non-conventional human leukocyte antigen-B27 free heavy chains may play in the pathogenesis of AS.

Limited Cutaneous Improvements Found in First Trial Using IL-6 Inhibitor in PsA

Limited Cutaneous Improvements Found in First Trial Using IL-6 Inhibitor in PsA

This Phase 2 trial of clazakizumab represented the first time an IL-6-targeted therapy has been evaluated in psoriatic arthritis.

Systematic Review of Feasible Anti-TNF Tapering Strategies in AxSpA

Systematic Review of Feasible Anti-TNF Tapering Strategies in AxSpA

Tapering of anti-TNF therapy can facilitate sustained remission or lower disease activity in most patients with axial spondyloarthritis while ameliorating both risk for adverse events and treatment costs.

Effects of Peer-Led Education on Quality of Life in Ankylosing Spondylitis

Effects of Peer-Led Education on Quality of Life in Ankylosing Spondylitis

This study attempted to quantify the effects of peer-led education on quality of life in patients with ankylosing spondylitis.

Increased Risk of Depressive Disorders in Ankylosing Spondylitis

Increased Risk of Depressive Disorders in Ankylosing Spondylitis

A recent study published in The Journal of Rheumatology found that patients with AS have an increased risk of developing certain depressive disorders following their diagnosis.

Sexual Dimorphism in Th17 Immune Axis Tied to Gender Differences in AS

Sexual Dimorphism in Th17 Immune Axis Tied to Gender Differences in AS

To examine a potential immunologic mechanism for sex differences in AS, researchers examined data from serum samples obtained from a cohort of females and males with AS and from sex- and age-matched controls.

USPSTF Draft Statement: Latent TB Screening For TNFi Users

USPSTF Draft Statement: Latent TB Screening For TNFi Users

The USPSTF concludes with moderate certainty a moderate net benefit in screening at-risk adults for latent tuberculosis infection (LTBI).

Predictive Value of Serum VEGF for Syndesmophyte Formation in AS With GOL Tx

Predictive Value of Serum VEGF for Syndesmophyte Formation in AS With GOL Tx

The development of advanced lesions in AS is thought to be influenced, in part, by vascular proliferation, with vascular endothelial growth factor (VEGF) playing a regulatory role in that process.

DMARDs and Incidence of Virus-Associated Malignancy in RA

DMARDs and Incidence of Virus-Associated Malignancy in RA

In this study, biologic DMARD therapy was not associated with an increased incidence of virus-associated cancers in female patients with inflammatory arthritis.

Case Study and Clinical Highlight: A Patient With Nephrotic Syndrome and Ankylosing Spondylitis

Case Study and Clinical Highlight: A Patient With Nephrotic Syndrome and Ankylosing Spondylitis

AA amyloidosis is a rare but significant complication of ankylosing spondylitis (AS) and may lead to proteinuria and renal dysfunction.

Are Biosimilars About to Make Waves in Rheumatology?

Are Biosimilars About to Make Waves in Rheumatology?

The growing use of expensive biologics has led public and private insurers in the United States to impose cost-sharing burdens that place these drugs out of reach for many patients. The FDA is anticipating a marked increase in the biosimilar market as more patents expire for brand-name biologics.

No Significant Increased Risk of Birth Defects in Offspring of Women on Anti-TNF Agents

No Significant Increased Risk of Birth Defects in Offspring of Women on Anti-TNF Agents

Women who received anti-TNF agents during pregnancy did not have a significantly higher risk of having children with birth defects.

Enteropathic Spondyloarthritis: A Review of Mechanisms and Effective Treatment Strategies

Enteropathic Spondyloarthritis: A Review of Mechanisms and Effective Treatment Strategies

Enteropathic spondyloarthritis (ESpA) encompasses a group of rheumatic disorders that share overlapping pathophysiology with other immune system disorders, particular those of the gut. Therefore, a multidisciplinary approach is important to recognizing the varied manifestations of ESpA in patients with IBD in order to achieve a prompt and accurate diagnosis leading to comprehensive care.

Sign Up for Free e-newsletters